View in EDS

Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.

Saved in:
Bibliographic Details
Title: Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
Authors: Thiam-Diouf A; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: Arame.Thiam@bcm.edu., Metch B; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP), United States. Electronic address: bmetch@fredhutch.org., Sharpe C; University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada. Electronic address: cameronjaysharpe@gmail.com., Mulugeta R; Yale University, New Haven, CT 06520, United States. Electronic address: robel.mulugeta@yale.edu., Andrasik MP; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: mandrasik@fredhutch.org.
Source: Vaccine [Vaccine] 2018 Feb 21; Vol. 36 (9), pp. 1235-1242.
Publication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29395528
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thiam-Diouf+A%22">Thiam-Diouf A</searchLink>; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: Arame.Thiam@bcm.edu.<br /><searchLink fieldCode="AU" term="%22Metch+B%22">Metch B</searchLink>; Fred Hutchinson Cancer Research Center, Statistical Center for HIV/AIDS Research and Prevention (SCHARP), United States. Electronic address: bmetch@fredhutch.org.<br /><searchLink fieldCode="AU" term="%22Sharpe+C%22">Sharpe C</searchLink>; University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada. Electronic address: cameronjaysharpe@gmail.com.<br /><searchLink fieldCode="AU" term="%22Mulugeta+R%22">Mulugeta R</searchLink>; Yale University, New Haven, CT 06520, United States. Electronic address: robel.mulugeta@yale.edu.<br /><searchLink fieldCode="AU" term="%22Andrasik+MP%22">Andrasik MP</searchLink>; HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., E3-300, PO Box 19024, Seattle, WA 98109, United States. Electronic address: mandrasik@fredhutch.org.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2018 Feb 21; Vol. 36 (9), pp. 1235-1242.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29395528
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.vaccine.2017.11.032
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1235
    Titles:
      – TitleFull: Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thiam-Diouf A
      – PersonEntity:
          Name:
            NameFull: Metch B
      – PersonEntity:
          Name:
            NameFull: Sharpe C
      – PersonEntity:
          Name:
            NameFull: Mulugeta R
      – PersonEntity:
          Name:
            NameFull: Andrasik MP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 02
              Text: 2018 Feb 21
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1873-2518
          Numbering:
            – Type: volume
              Value: 36
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Vaccine
              Type: main
ResultId 1